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bacter spp., classic pathogens ofinvasive dysenteric disease, are isolated in 1-
15% of cases. Vibrio species are most common in Asia. Less common
bacteria are Aeromonas hydrophila and Plesiomonas shigelloides. Parasitic
causes of TD include E. histolytica, G. lamblia and Cryptosporidium.
Viruses such as Rotavirus and Norwalk-like Virus have been isolated
from up to 12% of visitors to Latin America, Asia and Africa. The most
pragmatic approach to the prevention ofTD is the advice to "cook it, boil it,
peel it, or forget it". Prophylaxis with antinticrobials has been shown to be of
benefit in preventing TD with Trimethoprim-sulfamethoxazole and /luor-
oquinolones, but the routine use of these agents is generally not recom-
mended because of sideeffects of antibiotics and the development of
resistance. Antimicrobial prophylaxis can be discussed in patients with
inflammatory bowel disease, immunocompromised patients (HIV-infected
persons or transplant recipients) or patients for whom dehydration would be
dangerous. The mainstay of treatment is adaequate rehydration with oral
rehydration solution ev. supplemented with loperantide. Antimicrobials are
indicated in patients with severe abdominal pain, fever or dysentcry.
506 - Efflux pumps from basic science to the patients
IMoS23IAntibiotic efflux in dinically Important gram-
negative bacteria
Patrick Plesiat
Faculty of Medicine, Besan{on, France
Over the past decade, antibiotic efflux systems have been discovered in a
growing number ofbacterial pathogens. Extensive studies on Escherichia coli,
Pseudomonas aeruginosa and Neisseria gono"hoeae have led to the conclusion
that efflux pumps of the RND fantily play an essential role in the natural
resistance of these species to a vast array of inhibitors. For example, the
elevated intrinsic resistance ofP. aeruginosa to antibiotics mainly depends on
the expression of two poorly specific export systems (MexAB-OprM and
MexXY), the action of which is potentiated by the outer membrane
permeability barrier. In pathogens exhibiting more permeable outer mem-
branes, such as E. coli, efflux systems provide an efficient protection against
large or hydrophobic compounds (e.g. bile acids, defensins, and macrolides).
When overexpressed following mutations in regulatory genes, RND
pumps may produce clinically relevant resistance to a great many substrate
antibiotics (MICs x 2-16). Such efflux mutants have frequendy been
reported among clinical strains of P. aeruginosa. According to concordant
data, MexAB-OprM overproducers would account for 30 to 70% of the
carbenicillin resistance in hospital strains. The virulence status of the efflux
mutants however requires further investigations.
As demonstrated in E. coli and P. aeruginosa, efflux systems may have a
major impact on bacterial resistance when they are combined with other
mechanisms such as target alterations (DNA gyrase) or ,B-Iactamase produc-
tion. Furthermore, active export of antibiotics tends to increase the emer-
gence of highly resistant target mutants. For all these reasons, efBux
inhibitors would be invaluable drugs in the treatment of infections caused
by multidrug resistant strains.
IMoS241 Antibiotic efflux in dinically important Gram-positive
bacteria
Martin J. Gill
Division of Immunity & Infection, Medical School, University ofBirmingham,
Birmingham, United Kingdom
Efflux pumps are now well recognised in a number of Gram-positive
bacteria. The role of these pumps in normal physiology is unclear, but
their increased expression produces low-level antibiotic resistance Their role,
in combination with other resistance mechanisms, in producing clinical
significant resistance in is becoming increasingly important. Pumps which
appear to have a limited substrate range are macrolide pumps such as mefA
(Streptococcus pyogenes), mejE (Streptococcus pneumoniae) and mreA (Strepto-
coccus agalactiae) or the some oftet determinants (eg, tetK and tetL). The best
characterised pump in Staphylococcus aureus is NorA. Although Nora is
associated with quinolone resistance, it can use a wide range of substrates.
PmrA of Streptococcus pneumoniae is a pump similar to NorA. NorA and
PrnrA show structural and functional similarities to the efflux pumps Bmr
and Bit of Bacillus subtilis. However, it is likely that the regulation of Nora
and PmrA is different. Genome sequencing projects have indicated that
homologues to existing characterised pumps are found in a wide range of
bactena, Several pump. may exi.t in the .ame .train; homologues of Bmr,
Bit and EmrAB have been found in addition to Nora in a strain of
Staphylococcus aureus. Drugs which are not affected by efflux-mediated
resistance are being developed. Pump inhibitors are also being researched.
Efflux pumps can contribute to intrinsic antibiotic resistance. Their inactiva-
tion in different species is being developed as a sensitive tool for screening for
naturally occurring antimicrobial agents that would otherwise be effluxed
from the cell.
IMoS2S1 Efflux pumps in fungi. is it a real problem?
J. Bille
University Hospital, Lausanne, Switzerland
Mechanisms of resistance in yeasts and fungi are various and yet incomple-
tely worked out. Efflux pumps are implicated so far in acquired azole
resistance among yeasts, particularly Candida a/bicans, as well as some other
Candida species: C. glabrata, C. krusei, C. dublinimsis, C. tropicalis.
Evidence for their direct implication as mechanisms ofacquired resistance
in isogenie pairs or series ofclinical strains with increasing levels ofresistance
to fluconazole (F) are the following: i) increase efflux of azoles, as well as
other substrates of MDR transporters (rhodamine); ii) increase of mRNA
levels for MDR genes (CDR or MDR); iii) MDR gene over-expression in S.
cerevisiae confers resistance; iv) MDR gene deletion in C. albicans results in an
hypersusceptible strain.
So far, several efflux transporter genes have been characterised, belonging
either to the ATB Binding Cassette (CDR genes) or to the Major Facilitator
(BENr, FLU genes) transporters, conferring various degrees of cross-
resistance to azoles or other substrate•.
Clinical significance of efflux pumps mediated resistance in yeasts (parti-
cularly C. albicans) has been largely documented mainly in Aids patients
suffering from oropharyngeal candidiasis (OPC), particularly before
HAART. In other clinical settings, few cases have undoubtedly been
described where clinical resistance was correlated to acquired efBux mediated
F resistance after a short course of F. In a rat model ofendocarditis due to C.
albicans, inhibition of the efflux resistance mechanism by cyclosporin not
only restored the efficacy ofF to cure infection due to a F-resistant strain, but
also afforded significant better results than F alone when the strain was F-
susceptible.
Thus combining clinically administrable efflux pumps inhibitors to azoles
should be sought in order to improve the efficacy ofthis class ofantifungals.
507 - Glycopeptide resistance in Staphylococcus autefls
IMoS26IGlycopeptide resistance in Staphylococcus aureus
(GISA): From in vitro to in vivo
J. L. Mainardi, I. Podglajen
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Georges Pompidou, Paris, France
The recent description of intermediate (homogeneous and heterogeneous)
glycopeptide-resistance of Staphylococcus aureus (GISA) has raised concern
about the importance of this potential public heath problem. However, the
emergence of GISA i. not a new phenomenon. Teicoplanin-resistant
mutants of S. aureus selected in vitro have been reported in severallabora-
tories since 1990. These studies have shown that teicoplanin was a more
efficient selective agent than vancomycin, even if more recently a highly
vancomycin-resistant mutant (MIC = 100 p.g/ml) of S. aureus has been
selected by Sieradzki et al. O. Bacteriol. 1997; 179: 2557-2566) by a step-wise
pressure procedure with vancomycin. The first in vivo emergence of
teicoplanin resistance, during therapy, of S. aureus has also been reported
in 1990 (Kaatzet al. J. Infect. Dis. 1990; 162: 103-108) and in several studies
since. The isolation of GISA strains, often in patients which have received
prolonged therapy with glycopeptides, and the possibility to select mutants
from hetero-GISA with further increased resistance to glycopeptides, both in
vitro and in vivo, underline the necessity to monitor carefully the serum levels
of glycopeptide during therapy.
IMoS27IGlycopeptide resistance in Staphylococcus aureus:
Mechanlsm(s) of resistance
H. Labischinski
Pharma Research Center, Bayer AG, Wuppertal, Germany
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MethiciIlin-resistant Staphylococcus aureus (MRSA) has become one of the
most important nosocomial pathogens worldwide and poses serious infec-
tion control problems. As a rule, MRSA are multiresistant against many
antibiotics and increasingly vancomycin-type glycopeptides remain the only
rational treatment available. Recently, S. aureus strains with drastically
diminished vancomycin susceptibility have been isolated. first in Japan and
meanwhile in various regions of the world. Glycopeptide antibiotics exert
their action by interfering with the final steps ofbacterial cell wall synthesis
occurring at the outside of the bacterial cell. Remarkably, their mode of
action does not involve direct interference with the corresponding enzymes
(transpeptidases and transglycosylases) but binding to the enzyme substrates,
muropeptide building blocks. Analysis of the cell wall architecture of
laboratory mutants and. more important. clinical isolates reveal that present
GISA isolates can achieve reduced glycopeptide susceptibility by several
unrelated changes in amount and composition ofcell wall building blocks. In
spite of these distinct mechanisms. a unifying scheme quite distinct from that
described earlier for vancomyein-resistant enterococci will bc discussed.
Detailed understanding of the molecular resistance mechanisms and the
various factors involved in resistance phenoType expression is a prerequisite
to influence further spread of multiresistant staphylococci and to arrive at
new therapeutic alternatives.
IMoS2S1 Glycopeptide resistance in Staphylococcus auteUs
(GISA): Measures needed for control
J. Linares
Microbiology Dept. Hospital de Bellvitge. University of Barcelona, Barcelona,
Spain
The recent description in Japan, USA. France and Spain of methicillin
resistant S. aureus (MRSA) isolates with intermediate resistance to glyco-
peptides is of great concern. Recent surveys from different countries show
that there have been no major changes in susceptibility to glycopeptides in S.
aureus in the last decade, but GISA strains may have been missed because
these studies did not use optimal methods for their detection. In our hospital
927 patients (0.4 cases/loo adm.) acquiredMRSA fromJan 1990 to Dec 1998
and the majority of infections were caused by a multiresistant epidemic
Iberian clone. Screening ofGISA strains has been routinely performed in all
S. aureus (221 MRSA and 1430 MSSA) isolated since Jan 1998 to Dec 1999
and in a selected sample of244 MRSA strains isolated in the 1990-97 period,
by using plates with 2, 4 and 6 mg/L of vancomycin (V). No GISA were
detected among MSSA strains. The prevalence of GISA among MRSA
strains was 27.7% in 1990-94.14% in 1995-97,6.2% in 1998 and 1.8% in
1999. All GISA strains belonged to Iberian clone, showed MICs of4 mg/L of
V and were confirmed by population analysis profiles. The MRSA infection
control program was initiated in Feb-90 and was based on: 1) Clinical
laboratory-based surveillance 2) Isolation measures and reinforcement of
hand washing and 3) Mupirocine treatment ofMRSA carriers (pts and hew).
The monthly incidence rate decreased from a mean of0.57 cases/l 00 adm. in
the 1990-94 period to 0.33 cases/loo adm. in the 1996-98 period (p =
0.(04). A decrease in V use was observed from 1995 to 1998. The decrease in
the frequency of GISA strains in our hospital could be related to the
reduction of glycopeptide use, the efficacy of control measures and the
emergence ofa new MRSA clone with MIC of 1 mg/L ofV and susceptible
to gentamicin.
In conclusion, specific MRSA infection control programmes, rational
antibiotic policies including reduction ofglycopeptide use and good practice
are the key measures in reducing hospital acquired MRSA and GISA
infections. Active surveillance for MRSA and GISA must be maintained.
IMoS291 Therapeutic options for GISA
Alan P. Johnson
Cell/ral Public Health Laboratory, London, United Kingdom
Isolates of GISA reported to date have been obtained from patients who
failed treatment with vancomycin. Although the number ofpatients is small,
the repeated observation oftreatment failure indicates that agents other than
glycopeptides should be used to treat infections due to GISA.
The widespread concept of vancomycin as the "drug of last resort" for
MRSA, has lead many to suggest that emergence of vancomycin resistance
in MRSA would equate with untreatable infections. However. some GISA
isolates have remained susceptihle to a range of agents such as co-trimox-
azoic, gentamicin, tetracycline, chloramphenicol, rifampicin or quinupris-
tin/dalfopristin. Some patients with GISA infections have apparently been
successfully treated with non-glycopeptide agents, although additional
treatment components such as surgical intervention make assessment of
their efficacy difficult. Nevertheless, it would seem prudent to recommend
that therapy of infections with GISA be guided by the results of laboratory
susceptibiliTy testing. If necessary, this should inelude developmental agents
such as oxazolidinones. Laboratory studies with one clinical GISA isolate
have suggested a synergistic interaction between beta-Iactams and vanco-
mycin The role of combination therapy with these or other agents thus
merits further evaluation in vitro and in animal models. Should these or
other treatment options appear favourable. their successful clinical applica-
tion will depend on the rapid and reliable detection ofJow-level glycopep-
tide resistance in clinical isolates.,
508 - Nosocomial viral infections in pediatrics
IMoS30IMolecular tools for epidemiology
Tone Tenjum
Institute of Microbiology, Rikshospitalet (National Hospital), Oslo, Norway
The advent of molecular genotyping has provided a new basis for microbial
epidemiology. The most powerful tools in virology in this context to date
have been PCR based methods such as random amplified polymorphism
detection (RAPD) and PCR combined with restriction enzyme analysis
(PCR-REA) or DNA sequencing. More recently, multilocus sequence
Typing (MLST) has been introduced to provide improved resolution of
bacterial isolates and contributed to databases for the identification and
tracking of the global spread of virulent or drug-resistant pathogens. This
approach would be most suitable for viral pathogens. Molecular methods
have successfully been applied to solve questions on the epidemiology and
dissemination of viral infections of miscellaneous origin. Multiplex assays
detecting multiple agents and markers provide a rational basis for strain
typing. The use of these techniques to monitor drug resistance, mechanisms
and emergence ofinfectious disease by sequence polymorphisms has become
increasingly important. Patterns of drug resistance markers should be
correlated with the epidemiologic findings.
IMoS33! Hepatitis viruses
Anders Widell
Department of Medical Microbiology, University Hospital Malmo, Lund
University, Malmo, Sweden
Hepatitis A, a childhood infection in the developing world but disappearing
in Europe, readily spreads by the feco-oral route in closed settings and may
remain unrecognized ifanicteric. Occasional transmission has been reported
via blood or blood products. However, gammaglobulin or vaccination can
stop outbreaks.
Hepatitis B and C share the intravenous route of transmission and both
have previously been transmitted to multi-transfused children with leuke-
mia and thalassemia. Recently, we described two outbreaks ofhepatitis C in
a pediatric oncology service including 10 HCV genotype 3a cases (1990-3),
and 10 HCV genotype Ib cases (1993-4). Genetic analysis showed that only
a few strains had spread between the children. Many had high vira1 titres but
remained anti-HCV negative for long periods. Our analysis indicated that
transmission had occurred through violations of hygienic routines when
permanent intravenous catheters were flushed with fluids from contami-
nated multidose vials. This was supported by a closely monitored transmis-
sion event involving a child who became HCV genotype 3a infected when
treated at a ward for adults. In January 1995 all infected children were
transferred to the Department of Infectious Diseases. In parallel, hygienic
routines at thc oncology service were thoroughly overhauled, and no further
cases have occurred.
Our studies highlight the ease of spreading hepatitis C between patients
with intravenous catheters and who are exposed to multidose vials. in
particular if patients are immunosuppressed. Similar transmission mechan-
isms are also relevant for other blood borne agents like HBV, HIV and
malaria. etc.
